DrugDashboards

Furoscix

furosemide · FUROSEMIDE 80 mg/mL · Injection · Subcutaneous · scPharmaceuticals Inc., a wholly owned subsidiary of MannKind Corporation

NDC 71767-0111-01 · 1 SYRINGE, GLASS in 1 CARTON / 1 mL in 1 SYRINGE, GLASS · NDA · View full market →

The short version

11 companies supply this market — deep enough that no single failure threatens the supply. It is in shortage right now — FDA lists the reason as “requirements related to complying with good manufacturing practices”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$1,069.78
Reported to Texas DSHS · 2026 annual filing · Mannkind Corporation

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.6%chance of a new FDA shortage posting for furosemide (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · price up 19% YoY

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $6,229.65 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA209988
TE code
—
Approval date
Oct 7, 2022
Patents / exclusivity
4 patents, 0 exclusivities
TypeNumber / codeExpires
patent11433044Apr 3, 2034
patent9884039Apr 3, 2034
patent12370168Apr 3, 2034
patent10272064Apr 3, 2034

Shortage history

  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)Apr 7, 2020
    Requirements related to complying with good manufacturing practices
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)Apr 7, 2020
    Requirements related to complying with good manufacturing practices
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)Apr 7, 2020
    Requirements related to complying with good manufacturing practices
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of furosemide (Injection)

LabelerStrengthFirst seenLast seen
Hikma Pharmaceuticals USA Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Maiva Pharma Private LimitedFUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Amneal Pharmaceuticals LLCFUROSEMIDE 20 mg/2mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCFUROSEMIDE 40 mg/4mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCFUROSEMIDE 100 mg/10mLJul 15, 2026Sep 2, 2026
Civica, Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCFUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLC.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Micro Labs LimitedFUROSEMIDE 100 mg/10mLJul 15, 2026Sep 2, 2026
Micro Labs LimitedFUROSEMIDE 20 mg/2mLJul 15, 2026Sep 2, 2026
Micro Labs LimitedFUROSEMIDE 40 mg/4mLJul 15, 2026Sep 2, 2026
scPharmaceuticals Inc., a wholly owned subsidiary of MannKind CorporationFUROSEMIDE 80 mg/mLJul 29, 2026Sep 2, 2026
SQ Innovation, Inc.FUROSEMIDE 30 mg/mLJul 15, 2026Sep 2, 2026
ten23 health Valais AGFUROSEMIDE 8 mg/mLJul 15, 2026Sep 2, 2026
Accord Healthcare, Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Furoscix — NDC 71767-0111-01," retrieved September 3, 2026, https://drugdashboards.com/drug/71767011101.

Free to cite with attribution — see how the data is put together.